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Despite the lack of international agreement regarding the deﬁnition and classiﬁcation of ﬁber, there is established evidence on the
role of dietary ﬁbers in obesity and metabolic syndrome. Beta glucan (β-glucan) is a soluble ﬁber readily available from oat and
barley grains that has been gaining interest due to its multiple functional and bioactive properties. Its beneﬁcial role in insulin
resistance, dyslipidemia, hypertension, and obesity is being continuously documented. The fermentability of β-glucans and their
ability to form highly viscous solutions in the human gut may constitute the basis of their health beneﬁts. Consequently, the
applicability of β-glucan as a food ingredient is being widely considered with the dual purposes of increasing the ﬁber content
of food products and enhancing their health properties. Therefore, this paper explores the role of β-glucans in the prevention
and treatment of characteristics of the metabolic syndrome, their underlying mechanisms of action, and their potential in food
applications.
1.Introduction
Obesity has reached global epidemic proportions with more
than one billion adults aﬀected by this chronic disorder [1].
Coronary artery disease, stroke, insulin resistance, type 2
diabetes, hypertension, and metabolic syndrome are well-
known medical comorbidities associated with excess body
weight [2]. The metabolic syndrome is deﬁned by a com-
bination of three or more of the following: (a) abdominal
circumference >102cm (40  ) for men and 88cm (35  )
for women, (b) hypertension, (c) hyperglycemia, and (d)
dyslipidemia (elevated triacylglyceride concentrations and
low levels of high-density lipoproteins (HDL) in blood) [3].
It is directly associated with increased risk of type 2 diabetes
and cardiovascular diseases.
Many studies have examined the potential of diets and
dietary components as a ﬁrst-line intervention in the pre-
vention and treatment of metabolic syndrome [4]. Accord-
ingly, various dietary constituents, foods, and dietary prac-
tices, capable of controlling blood glucose, insulin and lip-
ids, blood pressure, and food intake have been identiﬁed.
Although the ideal dietary pattern for patients with meta-
bolic syndrome has not been deﬁned, there is growing ev-
idence that high intakes of fruits, vegetables, legumes, and
cerealsare beneﬁcial [5–11].Manyoftheirbeneﬁtshavebeen
attributed to their low-glycemic properties and their dietary
ﬁber content. However, dietary ﬁbers in fruits, vegetables,
legumes, and cereals are poorly deﬁned and vary greatly in
characteristics.
T h ef o c u so ft h i sr e v i e wi so nb e t ag l u c a n( β-glucan),
which is a dietary ﬁber readily found in oat and barley
bran. β-glucan is a relatively inexpensive milling byproduct,
and it is added to foods on the assumption that this will
contribute to health beneﬁts. β-glucans are predominantly
found in the internal aleurone and subaleurone cell walls
[12–14]. The content of β-glucan varies with environmental
conditions during endosperm development and is regulated
by (1→3, 1→4)-β-glucan endohydrolase (EC 3.2.1.73 also
known as licheninase or 1,3-1,4-beta glucanase) to facilitate
endosperm cell-wall degradation during germination [15].
Among cereals, the highest content (g per 100g dry weight)
of β-glucan has been reported for barley: 2–20g (65% is
water-soluble fraction) and for oats: 3–8g (82% is water-
soluble fraction). Other cereals also contain β-glucan but
in much lower amounts: sorghum 1.1–6.2g, rye 1.3–2.7g,
maize 0.8–1.7g, triticale 0.3–1.2g, wheat 0.5–1.0g, durum
wheat 0.5-0.6g, and rice 0.13g [16]. Other sources of β-
glucan include some types of seaweed [17]a n dv a r i o u s
species of mushrooms such as Reishi, Shiitake, and Maitake
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Canada is a major producer of both oats and barley,
producing 2297.6 and 7605.3 thousand metric tonnes of
oats and barley, respectively, in 2010/2011 [19, 20]. In 2007,
Canada was the 5th leading producer of barley and the 2nd
leading producer of oats worldwide [21]. Fractions rich in β-
glucansarereadilyobtainedfromcerealgrainsbydrymilling
followed by sieving and air classiﬁcation processes or by
wet milling followed by sieving and solvent extractions [22].
These approaches result in concentrates or isolates contain-
ing 8–30% and 95% β-glucans, respectively. During oat pro-
cessing, oat bran and aleurone layers can be milled from oat
groat, creating the bran as a major byproduct. Oat β-glucan
is found in greater concentrations in the bran as compared
to the whole-oat groat and commercial oat bran contains
7–10% β-glucan [23]. However, extraction of pure β-glucan
isolates is not straightforward and relatively costly since the
aleurone and subaleurone cell walls also enclose starch, pro-
tein, and lipids [24]. Thus, pure β-glucan isolates are often
ignoredinfoodproductdevelopmentandrelativelyinexpen-
sive oat and barley bran or ﬂour fractions are typically used.
The objective of the current review is to illustrate the
role of β-glucan, as a soluble and fermentable ﬁber, in the
prevention and treatment of various metabolic syndrome-
linked diseases. β-glucan is then compared to other soluble
and fermentable dietary ﬁbers, clarifying whether the eﬀects
of β-glucan on health and disease are unique. An overview
of deﬁnitions and types of ﬁber is provided ﬁrst and then
followed by an in-depth examination of the health beneﬁts
associated with β-glucan, its mechanisms of action, and its
potential food applications.
2.DietaryFibers:Characteristics,Deﬁnitions,
Classiﬁcations, andAnalyticalMethods
Scientiﬁc and regulatory bodies around the world deﬁne
ﬁber diﬀerently. The challenge of deﬁning ﬁber is probably
best exempliﬁed by the 10-year process that was required
to achieve an international legal deﬁnition for dietary ﬁber
by Codex [25]. Most deﬁnitions of ﬁber address its biolog-
ical, chemical, and nutritional characteristics while recent
regulatory requirements have created the need for analytical
deﬁnitions. Fibers can also be categorized based on their
physicalandchemicalpropertiesaswellastheirphysiological
eﬀects. The following sections outline some characteristics
of ﬁber, its various deﬁnitions and classiﬁcations as well as
the analytical approaches used for its quantiﬁcation. Prior
to an in-depth examination of β-glucan, a brief overview
describing the role of dietary ﬁbers in metabolic syndrome
will be given.
2.1. Characteristics of Dietary Fibers. Four categories of
ﬁber deﬁnitions have been identiﬁed [26], each of which
addresses a diﬀerent characteristic of ﬁber. In general,
these categories describe ﬁber based on its source, chemical
composition, digestibility, metabolic fate, and physiological
eﬀects. Depending on which characteristic is used to deﬁne
ﬁber, various carbohydrates can be included under the
deﬁnition. Each category of deﬁnitions has its advantages
anddisadvantagesandbecauseofthevariationinﬁbertypes,
a combination of diﬀerent approaches is usually necessary in
order to deﬁne ﬁber in a comprehensive manner.
Biological deﬁnitions describe the origins of ﬁber and
have historically referred to nonstarch polysaccharides from
plant cell walls. The earliest formal deﬁnition of ﬁber refers
to the source of ﬁber: “Dietary ﬁbre is the proportion of food
which is derived from the cellular walls of plants, which is
digested very poorly in human beings” [27]. This deﬁnition
was soon updated to include nondigestible polysaccharides
that are not part of the plant cell wall [28] ,i no r d e rt oa c -
count for storage carbohydrates such as guar gum. How-
bever, this deﬁnition remains limiting as ﬁbers can also be
obtained from animal, fungal, bacterial, and synthetic sour-
ces. Categorization based on source is also complicated by
the inability of analytical methods to distinguish ﬁber origin
[29].
Chemically, ﬁber can be described based on its chain
length and type of linkages between each monomeric unit.
This provides a very precise and unequivocal meaning; how-
ever, deciding on the appropriate chain length for ﬁber has
been diﬃcult. The Codex deﬁnition for ﬁber indicates that
ﬁ b e r sh a v ead e g r e eo fp o l y m e r i z a t i o n( D P )≥ 10, but also
includes a footnote that the decision on whether to include
c a r b o h y d r a t e sw i t haD P> 2 (i.e., oligosaccharides) is up to
national authorities [30]. Fibers can also be described based
on the chemical bonds between their monomeric units as
nonstarch polysaccharides are typically linked by β-linkages;
however, this speciﬁcation would exclude resistant starches,
which contain α-1,4 linkages.
The physiological eﬀects of ﬁber refer to its nondigest-
ibility and metabolic eﬀects. Nondigestibility in the small
intestine is fundamental to ﬁber and was part of the ﬁrst
deﬁnition put forth by Trowell [27]. However, nondigest-
ibility and a lack of absorption by the small intestine alone
do not guarantee favourable physiological eﬀects. Depend-
ing on physicochemical properties, ﬁbers have a range of
physiological consequences including viscosity in the upper
gastrointestinal tract [31, 32], fermentation in the co-
lon [33], and prebiotic eﬀects [34, 35]. These eﬀects in the
gastrointestinal tract improve laxation and increase stool
bulking and also have metabolic consequences including
improvements in serum lipids and postprandial glycemia
and promotion of satiety.
Analytical deﬁnitions are used for labelling and inspec-
tion purposes. They often describe an “oﬃcial method,”
which is simple and reproducible enough to minimize dis-
pute. The risk with these types of deﬁnitions is that they are
not able to recognize new ﬁber compounds, which may have
signiﬁcant and beneﬁcial health implications. Consequen-
tially, the “oﬃcial method” has to be continually updated
to measure these new compounds. This type of deﬁnition is
very practical from a regulatory point of view; however, it
alone does not actually describe any characteristics of ﬁber
and an analytical method should only be part of a formal
regulatory deﬁnition.
2.2.DeﬁnitionsofDietaryFibers. Themostrecentdeﬁnitions
f o rﬁ b e rg e n e r a l l ya d d r e s sa tl e a s to n eo ff o u rc h a r a c t e r i s t i c s :
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digestion, and (4) beneﬁcial biological eﬀects. With the ad-
vances of food science, isolation, modiﬁcation, and synthesis
of many ﬁbers are possible, which have resulted in some
jurisdictions distinguishing between naturally occurring
ﬁbers from plant source and isolated or synthesized ﬁbers.
Others have chosen not to adopt this division by either
considering all nondigestible carbohydrates as ﬁber or only
those carbohydrates that are intrinsic and intact in plants.
Table 1 lists examples of such deﬁnitions based on this
division.
2.3. Classiﬁcation of Dietary Fibers. As seen in the previous
section, ﬁbers are often classiﬁed by their source (plant,
animal, isolated, synthetic, etc.), but they can also be clas-
siﬁed according to chemical, physical, or physiological cri-
teria [36, 37].
2.3.1. Chemical (Polymer Length and Types of Linkages).
Chemical classiﬁcation can divide carbohydrates based on
their chain length, or DP: sugars (DP 1-2), oligosaccharides
(DP 3–9), and polysaccharides (DP ≥ 10). Oligosaccharides
areeither(a)maltodextrins(α-glucans),principallyresulting
from the hydrolysis of starch, or (b) non-α-glucan such as
raﬃnose and stachyose, fructo- and galactooligosaccharides
and other oligosaccharides. Polysaccharides may be divided
into starch (α-1,4 and 1,6 glucans) and nonstarch polysac-
charides, which primarily consist of plant cell wall polysac-
charidessuchascellulose,hemicelluloses,andpectinbutalso
includesplantgums,mucilages,andhydrocolloids.However,
some carbohydrates do not ﬁt into this categorization. For
instance, inulin may have from 2 to 200 fructose units and
thus can be both oligo- and polysaccharide [35].
2.3.2. Physical (Solubility and Viscosity). Fibers are most
commonly characterized based on their solubility. Distinc-
tion between soluble and insoluble dietary ﬁbers is based on
the solubility characteristics of dietary ﬁber in hot aqueous
buﬀer solutions [38]. Solubility of dietary ﬁber structure
cannot be simply described as the solubility in water. Sol-
ubility of dietary ﬁbers is rather deﬁned as dissolved or
liqueﬁed in a buﬀer and enzyme solution modeled after, but
not necessarily identical to, the aqueous enzyme solutions
or slurries present in the human system [39]. Insoluble ﬁ-
bers primarily consist of cellulose and some hemicelluloses,
resistant starch, and chitin while soluble ﬁbers include pec-
tins, β-glucans, galactomannan gums, mucilages, and some
hemicelluloses. Solubility can be used as a means to broadly
characterize the physiological eﬀects of ﬁbers. In general,
insoluble ﬁbers increase fecal bulk and the excretion of
bile acids and decrease intestinal transit time (i.e., laxative
eﬀect). Soluble ﬁbers increase total transit time by delaying
gastric emptying and also slow glucose absorption [40].
Although this characterization of ﬁber is used to generalize
the eﬀects of each ﬁber type, only soluble viscous ﬁbers delay
gastric emptying time and slow glucose absorption while
nonviscous soluble ﬁbers primarily act as a substrate for
microbial fermentation in the colon [33].
2.3.3. Physiological (Rate of Digestion and Fermentation).
The rate at which a carbohydrate is digested is determined by
anumberoffactors,includingtherateatwhichcarbohydrate
leaves the stomach and becomes available for absorption
as well as diﬀusion of released sugars occurs from food
bolus [41]. Thus, the rate at which carbohydrates leave
the food matrix and the ability for amylase to act on
the carbohydrate is an important determinant of glucose
absorption rate and resulting blood glucose levels. Based
on digestion, carbohydrates can be categorized as rapidly
or slowly digested or even resistant. Resistant carbohydrates
include plant cell wall polysaccharides, gums, fructans,
resistant maltodextrins, and resistant starches.
These carbohydrates that resist digestion make their way
to the large intestine, where they may be fermented by the
gut microﬂora [33]o rh a v ep r e b i o t i ce ﬀects [34]. However,
not all ﬁber is fermented. Short-chained fatty acids produced
fromfermentationaremainlysourcedfromresistantstarches
[42, 43]. Insoluble ﬁbers (e.g., lignins, cellulose, and some
hemicelluloses) are resistant to fermentation while soluble
ﬁbers (e.g., pectins, gums, mucilages, and some hemicellu-
loses) are more completely fermented by colonic microﬂora
[33]. A prebiotic is a nondigestible food ingredient that
selectively stimulates the growth and/or activity of a limited
number of colonic bacteria and subsequently improves host
health [44]. Prebiotic ﬁbers alter the balance of the gut
microﬂora towards what is considered to be a healthier one
[34] and includes fructans and resistant starches [45].
2.4. Analytical Methods for Fiber Quantiﬁcation. For food la-
belling purposes, it is important that analytical methods
complement the ﬁber deﬁnition in a given jurisdiction.
Fibers are typically measured by enzymatic-gravimetric
methods, although there are also gravimetric, nonenzy-
matic-gravimetric, and enzymatic chemical methods. High-
performance liquid chromatography (HPLC), gas liquid
chromatography (GLC), and ion-exchange chromatogra-
phy are also used [29]. Fibers recovered with enzymatic-
gravimetric methods include cellulose, hemicelluloses, pec-
tins, some other nonstarch polysaccharides, lignin and some
resistant starch. Soluble and insoluble ﬁbers can also be
measured separately by this method [46]. However, these
methods do not capture inulin and polydextrose and par-
tially measure resistant starch. To remedy this, separate
procedures have been proposed to quantify these other
compounds. For instance, β-glucans can be measured by
AOAC method 995.16, AAC method 32-23, and a method
by McCleary and Codd [47]. Resistant starch, oligofructan,
inulin, fructo-oligosaccharides, and polydextrose can also be
measured independently by several methods [29].
However, these methods incompletely measure all ﬁbers
included in the Codex deﬁnition, and the use of some or all
of these methods could result in underestimation of some
ﬁbers as well as overestimation of others due to double
counting. The McCleary method [48] (AOAC 2009.01) was
proposed to accompany the Codex deﬁnition as it allows for
measurement of a complete range of dietary ﬁber compo-
nents, including nondigestible oligosaccharides and resistant
starches, in one test, without double counting or missing4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 1: Categorization of recent deﬁnitions of ﬁber based on whether or not a distinction in dietary ﬁber source is made.
Plant source only
Food and Agriculture Organization (FAO)/World Health Organization (WHO):
“Dietary ﬁbre consists of intrinsic plant cell wall polysaccharides” [40]
Categorize ﬁber types based on source
Institute of Medicine (IOM):
“Dietary ﬁber consists of nondigestible carbohydrates and lignin that are intrinsic and intact in plants
Functional ﬁber consists of isolated, nondigestible carbohydrates that have beneﬁcial physiological eﬀects in humans
Total ﬁbre is the sum of dietary ﬁbre and functional ﬁber” [368]
Health Canada1:
“Dietary ﬁbre consists of the endogenous components of plant material in the diet which are resistant to digestion by enzymes produced by
humans. They are predominantly nonstarch polysaccharides and lignin and may include, in addition, associated substances” [369]
“Novel Fibre or Novel Fibre Source means a food that is manufactured to be a source of dietary ﬁbre, and
(i) that has not traditionally been used for human consumption to any signiﬁcant extent, or
(ii) that has been chemically processed, for example, oxidized, or physically processed, for example, very ﬁnely ground, so as to modify
the properties of the ﬁbre contained therein, or
(iii) that has been highly concentrated from its plant source” [370]
Codex Alimentarius Commission2:
“Dietary ﬁbre means carbohydrate polymers with ten or more monomeric units, which are not hydrolysed by the endogenous enzymes in
the small intestine of humans and belong to the following categories:
(i) edible carbohydrate polymers naturally occurring in the food as consumed,
(ii) carbohydrate polymers which have been obtained from food raw material by physical, enzymatic, or chemical means and which
have been shown to have a physiological eﬀect of beneﬁt to health as demonstrated by generally accepted scientiﬁc evidence to
competent authorities,
Synthetic carbohydrates polymers which have been shown to have a physiological eﬀect of beneﬁt to health as
demonstrated by generally accepted scientiﬁc evidence to competent authorities” [30]
No categorization of ﬁbers based on source
European Food Safety Authority (EFSA):
“Nondigestible carbohydrates plus lignin” [371]
Food Standards Australia New Zealand (FSANZ), formerly Australia New Zealand Food Authority (ANZFA)
“Dietary ﬁbre means the fraction of the edible part of plants or their extracts, or synthetic analogues that
(a) are resistant to the digestion and absorption in the small intestine, usually with complete or partial fermentation in the large
intestine;
(b) promote one or more of the following beneﬁcial physiological eﬀects:
(i) laxation,
(ii) reduction in blood cholesterol,
(iii) modulation of blood glucose,
and includes polysaccharides, oligosaccharides (DP < 2), and lignin” [372]
1Health Canada is currently reviewing its deﬁnition for ﬁber and proposed a new deﬁnition in December 2010 which has not yet been accepted [373].
2Two footnotes have been included with this deﬁnition, the ﬁrst indicates that substances associated with ﬁbre (e.g., lignin, waxes, saponins, etc.) are included
in this deﬁnition, unless they are isolated and reintroduced into a food. The second footnote states that the decision on whether to include carbohydrates from
3 to 9 monomeric units is up to the discretion of national authorities.
ﬁbercompounds[48].Thismethodusesextendedenzymatic
digestion at 37◦C, followed by gravimetric isolation and
quantitation of high-molecular weight dietary ﬁber and
liquid chromatography to quantitate low-molecular weight
dietary ﬁbers [49]. It is also particularly important for food
labelling that ﬁber analysis be completed on foods as they
w o u l db ee a t e ni no r d e rt op r o v i d em o r ea c c u r a t eﬁ b e r
values that account for the eﬀects of processing and cooking
procedures [49].
For analysis of β-glucan, two AOAC methods have been
adoptedinoats,barley,andtheirproducts.Bothmethodsare
enzymatic colorimetric methods that use lichenase to cleave
1,3 β-bonds in β- g l u c a nt op r o d u c eo l i g o s a c c h a r i d e so f
various lengths that are subsequently hydrolyzed to glucose
with amyloglucosidase, and then the glucose is assayed
colorimetrically[39].TheAOACmethod992.28isapplicable
to measure 1–12% β-glucans in oat and barley fractions,
unsweetened oat cereals, and ready-to-eat cereals [50]. The
AOAC method 995.16 is used to analyze β-glucan content in
ﬂoursfromwholegrains, milling fractions,and unsweetened
cereal products [47]. In addition to AOAC methods, there
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assay (ELISA) [51], near-infrared spectroscopy [52], and
ﬂuorescence assay of complex formed between β-glucan and
calcoﬂuor[53],whichareallspeciﬁcallydesignedtomeasure
β-glucan.
2.5. Dietary Fibers in the Prevention and Treatment of Meta-
bolic Syndrome. Dietary ﬁbers have been strongly implicated
in the prevention and treatment of various characteristics
of the metabolic syndrome. The beneﬁcial eﬀect of ﬁber-
rich foods and isolated ﬁbers, both insoluble and soluble,
on obesity, cardiovascular diseases, and type 2 diabetes has
been shown in randomized studies [6, 11] .D i e t sr i c hi n
ﬁber improve glycemic control in type 2 diabetes [54],
reduce low-density lipoprotein (LDL) cholesterol in hyper-
cholesterolemia [55–57], and contribute positively to long-
term weight management [58]. In epidemiological studies,
positive associations were noted between increased cereal
consumption, a source of both insoluble and soluble ﬁbers,
and reduced risk of metabolic syndrome, cardiovascular
diseases, and markers of systemic inﬂammation [59–61].
Diets rich in whole-grain foods have also been negatively
associated with metabolic syndrome [6, 8, 11].
In comparison to insoluble ﬁbers, soluble ﬁbers are more
potent in attenuating the presence of components of the
metabolic syndrome in both animals and humans. Addition
of α-cyclodextrin, a soluble dietary ﬁber, to high-fat-diet-
fed male Wistar rats for 6 weeks attenuated weight gain
and increases in plasma cholesterol and triglyceride levels
while also preventing increased fecal fat content relatively
to the control high fat diet [62]. Serum leptin levels were
normalized and insulin sensitivity index was improved. A
diet supplemented with the soluble ﬁbers from Plantago
Ovata husks (psyllium) and methylcellulose over 10 weeks
improved obesity and lipid proﬁle and ameliorated the
unbalanced secretions of the inﬂammatory tumor necrosis
factor-α (TNF-α) and adiponectin by the visceral adipose
tissue in obese Zucker rats [63]. The diet supplemented
with the soluble fermentable ﬁber Plantago Ovata husks also
resulted in the greatest improvement in hyperinsulinemia
and hyperleptinemia, and lowered the production and
accumulation of lipids in the liver. This eﬀect was associated
withactivationoftheAMP-activatedproteinkinase(AMPK)
system [63], known to increase fatty acid oxidation and
decrease fatty acid synthesis [64]. In humans, a daily intake
of at least 5g of soluble ﬁber, particularly from whole-
grain foods and fruits, reduced the presence of metabolic
syndrome in patients with type 2 diabetes by 54% [65].
Moreover, a high ﬁber meal, in which reﬁned-wheat ﬂour
wasreplacedwithwhole-wheatﬂour(16.8g/meal),increased
postprandial adiponectin concentrations in diabetic females
[66]. In a cross-sectional study on diabetic men, adiponectin
levels were 19% higher in the highest quintile of cereal ﬁber
intake than in the lowest quintile [67]. High adiponectin
levels are associated with improved glycemic control and
insulin sensitivity, a more favorable lipid proﬁle and reduced
inﬂammation in diabetic females [68].
Among soluble ﬁbers, β-glucan is the most frequently
consumed and is associated with reduced presence of insulin
resistance, dyslipidemia, hypertension, and obesity. The role
of β-glucan in the prevention and treatment of these de-
terminants is discussed in the following sections.
3.Beta Glucan,Obesity,
andMetabolicSyndrome
Increased interest in β-glucan in the last two decades arises
from its functional and bioactive properties. Of all ﬁbers, its
health beneﬁts have been the most extensively documented,
and the use of health claims with β-glucan-containing foods
has been allowed in several countries including Canada, the
United States of American, Sweden, Finland, and the United
Kingdom [69]. Moreover, no human adverse eﬀects have
been reported following the consumption of a diet rich in
β-glucan from oat or barley ﬂour or their extracts [70].
3.1.DeﬁnitionofBetaGlucan. Glucansareglucosepolymers,
classiﬁed according to their interchain linkage as being
either α-o rβ-linked [71]. β-glucans are a heterogeneous
group of nonstarch polysaccharides, consisting of D-glucose
monomers linked by β-glycosidic bonds [72]. The macro-
molecular structure of β-glucan depends on both the source
and method of isolation. The simplest glucan is the linear
and unbranched β-(1,3)-D-glucan, found among prokary-
otes and eukaryotes [73]. Another simple structural type
occurs mostly in the nonligniﬁed cell walls of cereal grains,
and consist of linear β-(1,3;1,4)-D-glucans [74]. Glucans
from barley, oats, or wheat are found in cell walls of the
endosperm, while being concentrated in the aleurone layer
of barley, oats, wheat, sorghum, and other cereals. Branched
structures of β-glucans consist of β-(1,3)- or β-(1,4)-glucan
backbonewitheither(1,2)-or(1,6)-linkedβ-glucopyranosyl
side branches [71]. They are major structural components of
the cell walls of yeast, fungi, and some bacteria [75]. The side
branched β-(1,3;1,2)-D-glucan is only present in the type
37 capsule of the bacterium Streptococcus pneumonia [73].
Branched β-(1,4;1,6)-D-glucanandβ-(1,3;1,6)-D-glucanare
found in diﬀerent groups of yeast, fungi, and algae [71]. In
algae, β-glucans are present as storage polysaccharides or cell
wall components. Some cyclic (1,2) and (1,3;1,6) β-glucans
were also isolated from various bacteria. These glucans
are important for plant-microbe interactions, and act as
signalling molecules during plant infection [76]. Besides
diﬀerences in type of linkage and branching, β-glucans can
vary in terms of frequency and length of branching, degree
of branching, molecular weight (from 102 to 106 daltons),
polymer charge, and/or solution conformation (random
coil or triple or single helix) as well as solubility [77].
All these factors play a role in shaping β-glucan-associated
biological activities, and should be taken into consideration
by researchers when discussing the physiological impacts of
β-glucans.
The β linkages in the polymer render β-glucan nondi-
gestible [78]. Moreover, β glucans are highly fermentable
in the caecum and colon [79]. In comparison to other oat
fractions, β-glucan induced the maximum growth rate and
cell proliferation rate of bacteria isolated from human
intestine and the maximum lactic acid productions [80].6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
The solubility of β-glucans is highly inﬂuenced by their
structures[81].However,nosharpdistinctionexistsbetween
the insoluble and soluble fractions and the ratio is highly
dependent on the extraction conditions of the soluble
ﬁber [82]. The (1→3)-β-glucans with a high degree of
polymerization (DP > 100) are completely insoluble in water
[83]. This conformation allows for stronger interactions
and associations between chains than between the chains
and water molecules. Solubility increases as the degree of
polymerization is lowered. The composition of the side
substituted branches and the frequency of these branches
also determine the solubility of β-glucan molecules [84]. A
single (1→6)-β linked glucose side can transform the glucan
i n t oam o r es o l u b l ef o r mi nc o m p a r i s o nt oi t su n b r a n c h e d
molecule[85].Moststudieshaveexaminedthestructureand
properties of water-soluble β-glucans, in contrast to water-
insoluble ones [86, 87].
Depending on physicochemical characteristics, various
biological functions of β-glucans have been described. This
review elaborates on the role of β-glucans in the preven-
tion and treatment of the metabolic syndrome; however,
a description of the immunomodulatory functions of β-
glucans will be brieﬂy examined in the following section.
3.2. Beta Glucan and Immunomodulation. Among polysac-
charides that act as immunostimulants, β-glucans were
found to be the most eﬀective against infectious diseases and
cancer [88]. The immunological potency of β-glucans varies
with the molecular mass, solution conformation, backbone
structure, degree of branching as well as the cell type that is
targeted [89].
T h er o l eo f1 , 3β-glucans from yeast, fungi, mushrooms,
and seaweed as biological immunomodulators has been well
documented in the past 40 years [90]. In vitro, animal
and human studies have shown that 1,3 β-glucans can en-
hance the responsiveness and function of immune cells,
stimulating both humoral and cellular immunity [91]. In
vitro studies demonstrated that β-glucans can enhance the
functional activity of macrophages and activate the anti-
microbial activity of mononuclear cells and neutrophils
[72, 92]. In vivo studies of a variety of β-glucans on the
responses to pathogen infections in animals have observed
increased microbial clearance and reduced mortality in
lethally infected animals when exposed toβ-glucans [93, 94].
Very few human studies examined the immune function of
β-glucans. Three clinical studies demonstrated that pretreat-
ment of high-risk surgical patients with intravenous yeast
β-(1,3; 1,6)-D-glucan decreased the infection incidence,
shortened intensive care unit length stay, and improved
survival in comparison to a saline placebo injection [95–97].
3.3. Beta Glucan and Parameters of the Metabolic Syndrome.
There is growing interest in the understanding of the asso-
ciation between β-glucans and determinants of the metabol-
ic syndrome. Most studies have used plant β-glucans as
functional viscous dietary ﬁbers in the management of
various components of the metabolic syndrome. Only two
studies described a protective role of nonplant β-glucans in
metabolic syndrome. In obese hypercholesterolemic men,
consumption of 12g of yeast β-(1,3;1,6)-D-glucan over
8 weeks lowered total cholesterol concentrations, and in-
creased HDL-cholesterol levels only 4 weeks after discontin-
uation of glucan intake [98] .O n es t u d yc o m p l e t e di nm i c e
found that eﬀects of chronic consumption of chitin-glucan
from a fungal source improved metabolic abnormalities
induced by a high fat diet [99]. Chitin-glucan is a cell wall
polysaccharide-based three-dimensional network in which
the central core contains branched chitin-β-1,3 glucan. In
this particular study, chitin-glucan decreased high fat diet-
induced body weight gain, fat mass development, fast-
ing hyperglycemia, glucose intolerance, hepatic triglyceride
accumulation, and hypercholesterolemia, irrespective of ca-
loricintake.Thesebeneﬁcialeﬀectsweremainlyattributedto
restorationofthecompositionand/oractivityofgutbacteria.
Theabilityofplantβ-glucans,whichwillbereferredtoas
“β-glucans” in the following sections, to form highly viscous
solutions in the human gut is thought to be the basis of its
health beneﬁts. These beneﬁts include lowering postprandial
glucose and insulin responses, decreasing cholesterol levels,
and potentiating the feelings of satiety. Beta glucan has the
ability to form highly viscous solutions because it is a linear,
unbranched, nonstarchy polysaccharide composed of β (1–
4) and β (1–3)-linked glucose molecules [100]. However,
the viscosity of β-glucan depends on the molecular weight,
solubility, and concentration [100–102]. For instance, high
molecular weight β-glucans produce a higher viscosity than
β-glucans with low molecular weights. Whether the ability to
form highly viscous solutions at low concentrations provides
β-glucan with unique health beneﬁts in comparison to other
soluble and fermentable dietary ﬁbers has received little
investigation.Theroleofβ-glucancomparedtoothersoluble
ﬁbersinaﬀectingthecomponentsofthemetabolicsyndrome
will be discussed in the following sections.
3.3.1. Beta Glucan and Insulin Resistance. Insulin resistance,
whether or not accompanied with hyperglycemia, and type 2
diabetes are well-established components of metabolic syn-
drome [103].
Several soluble ﬁbers, including β-glucan, psyllium and
guar gum, reduce postprandial glucose and insulin res-
ponses, and improve insulin sensitivity both in diabetic and
nondiabetic individuals [104–110]. In healthy individuals, a
beverage containing 25g/200mL each of resistant dextrins
or soluble corn ﬁber, a class of soluble ﬁbers isolated from
wheat or corn, attenuated postprandial glycemic, and insu-
linemic responses relatively to a control glucose solution
(25gglucose/200mL of the test beverage) [111]. Arabinoxy-
lan consumption, at 15g/day over 6 weeks, signiﬁcantly
lowered the postprandial responses of serum glucose and
insulin to a liquid meal challenge test in overweight subjects
with impaired glucose tolerance [112]. In stroke-prone
spontaneously hypertensive rats, psyllium supplementation
(5%) prevented insulin resistance in response to a high-
c a l o r i cd i e tg i v e nf r o m5t o9w e e k so fa g e[ 113].
Beta glucan also contributes to glycemic control. Sev-
eral factors were found to inﬂuence such an interaction,
including dose, food form, and molecular weight. Dose of
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ﬁber on glycemic responses. Relative to other ﬁbers, smaller
amounts of β-glucan are required to bring about reductions
in postprandial glucose and insulin responses in healthy
subjects [114, 115], type 2 diabetic patients [116, 117]a n d
moderately hypercholesterolemic men and women [118].
In subjects with noninsulin-dependent diabetes mellitus,
consumption of three breakfasts with 4, 6, and 8.6g of oat β-
glucan in a breakfast cereal signiﬁcantly decreased the peak
and average increases in glucose and insulin as compared
to the control [116]. A signiﬁcant relationship between the
amount of β-glucan in cereals and plasma glucose peak or
area under the glucose curve was also observed. Similarly,
a linear dose-dependent decrease in glycemic responses was
noted in response to breads containing varied doses of barley
β-glucan ranging from 0.1% to 6.3% [119]. Consumption
of oat bran providing 7.3g β-glucan in a breakfast cereal or
6.2g in a bar lowered postprandial glucose responses more
than an oat bran breakfast cereal providing 3.7g β-glucan
in type 2 diabetic subjects [120]. The consumption of oat
bran ﬂour containing 9.4g of β-glucan lowered postprandial
glycemia in type 2 diabetic patients in comparison to a
glucose load [117]. In addition, oat bran crisps containing
3gofβ-glucan also reduced postprandial glycemia, although
the reduction was only half as large as the eﬀect induced
by oat bran ﬂour containing 9.4g β-glucan. In hypercholes-
terolemic individuals, the addition of 5g of oat β-glucan
per day to a beverage consumed for 5 weeks attenuated
both glucose and insulin responses compared to the control
beverage [121]. However, in healthy individuals, larger doses
of β-glucan are needed in order to alter their glycemic
homeostasis. Unlike diabetic subjects [117] ,a3 go a tβ-
glucan dose did not aﬀect postprandial glycemic response in
healthy subjects [122] while the intake of muesli with 4g oat
β-glucan lowered postprandial blood glucose responses in
comparison to a reference meal without muesli and β-glucan
in healthy individuals [122, 123].
Food form has also an inﬂuence on β-glucan’s regulation
of glycemia. Incorporating a high dose of oat bran β-glucan
(5.2g) into fettucini did not signiﬁcantly lower postprandial
blood glucose relative to the fettucini alone in healthy
subjects [124]. This is perhaps because wheat pasta itself
has a low glycemic response. Molecular weight is another
determinant of viscosity in addition to the concentration
[101], and modulates the inﬂuence of β-glucan on glycemia.
A drink containing 5g of oat β-glucan with a molecular
weight 70000Da signiﬁcantly lowered postprandial glucose
and insulin levels relative to a rice drink control, while a
similardrinkcontainingbarleyβ-glucanofmolecularweight
40000Da had no eﬀect [121].
Reduced insulin responses have consistently been ob-
served following the ingestion of β-glucan [122, 125–127].
As in the case of glycemia, dose is an important factor in
shaping insulin responses to β-glucan. A consistent decrease
in insulin secretions was dose-dependently observed in over-
weight individuals in response to oat β-glucan, with sig-
niﬁcant changes reported at a dose of at least 3.8g of β-glu-
can [127]. Some studies have found the impact of β-glucan
on insulinemia to be independent of its glycemic eﬀect.
In healthy men, barley-enriched pasta, containing 5g of
β-glucan, induced a signiﬁcant reduction in insulinemia
in comparison to the control pasta without any apparent
eﬀect on glycemia [128]. Similarly, in healthy subjects, the
ingestion of 50g rye bread, containing 5.4g of β-glucan,
reduced postprandial insulinemic responses without a par-
allel reduction in glucose responses as compared with the
control bread [109]. It was hypothesized that the low
glycemic indices of pasta and rye bread may attenuate the
eﬀects of β-glucan on glucose responses.
Several mechanisms have been suggested to explain the
glucose- and insulin-lowering eﬀects of soluble ﬁbers, more
precisely β-glucan. One of the mechanisms includes the abil-
ityofsolubleﬁberstoformviscoussolutions.Delayedgastric
emptying occurs with increased digesta viscosity [129–
131], slowing subsequent digestion and absorption [132].
High digesta viscosity decreases enzyme diﬀusion [133]a n d
stimulates the formation of the unstirred water layer [134],
decreasing glucose transport to enterocytes [31]. Reducing
theviscosityofguargumfollowingacidhydrolysisresultedin
concurrent loss of its clinical eﬃcacy[31]. A relationship was
noted between guar gum viscosity and its glycemic response.
Moreover, it was stated that the viscosity of β-glucan could
account for 79–96% of the changes in glucose and insulin
responses to 50g glucose in a drink model [135].
Evidence for delayed stomach emptying following the
consumption of β-glucan emerged from human and animal
studies. The quantity of exogenous glucose appearing in
plasma was 18% lower, during the ﬁrst 120min, following
the polenta meal with 5g oat β-glucan in comparison to
the control polenta meal in overweight individuals [136].
Similarly, the addition of 13C-labelled glucose to a meal
containing 8.9g β-glucan, consumed over 3 days, lowered
the appearance of exogenous 13C-glucose in plasma by 21%
relatively to a control meal without β-glucan [137].
Short-chain fatty acids resulting from the anaerobic bac-
terial fermentation of soluble dietary ﬁbers such as β-glucan
in the colon [138]o ﬀer another explanatory mechanism
for the protective eﬀects of soluble ﬁbers on glucose and
insulin homeostasis. The short-chain fatty acids propionic
and butyric acid increased muscle expression of the insulin-
responsive glucose transporter type 4 (GLUT-4) via the
peroxisome proliferator-activated receptor (PPAR) γ [113].
The activation of PPARγ also increased GLUT-4 content in
adipocytes [139]. Stroke-prone spontaneously hypertensive
rats consuming psyllium supplementation, at 5% in a high
caloric diet, witnessed improved muscle insulin sensitivity
via short-chain fatty acid-induced increased membrane
GLUT-4 expression in comparison to cellulose supplemen-
tation [113].
In conclusion, due to its viscosity and fermentability,
β-glucan plays a signiﬁcant protective role against insulin
resistance in various populations.
3.3.2. Beta Glucan and Dyslipidemia. Individuals with meta-
bolic syndrome often present with atherogenic dyslipidemia,
characterized by elevated concentrations of triacylglycerols
and low levels of HDL cholesterol in blood [3]. This lipid
proﬁle presents an individual with a high risk for cardiovas-
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Soluble ﬁbers have the most reported beneﬁcial eﬀects
on cholesterol metabolism. In a meta-analysis, soluble ﬁbers
pectin, psyllium, oat bran, and guar gum were all proven
to be equally eﬀective in reducing plasma total and LDL
c h o l e s t e r o ll ev el s[ 55]. When included within a low saturated
fat and cholesterol diet, soluble ﬁbers lowered LDL choles-
terol concentrations by 5–10% in hypercholesterolemic and
diabetic patients [55, 108]. The consumption of 14g per day
of Plantago Ovata husk for 8 weeks induced a signiﬁcant
reduction in total cholesterol, LDL cholesterol, and oxidized
LDL in mild-moderate hypercholesterolemic patients [140].
Conversely, soluble ﬁbers from barley, oats, psyllium, and
pectin had no eﬀect on HDL cholesterol levels [55, 141].
Variable eﬀects of soluble ﬁbers on triglyceridemia have
been noted. In two meta-analyses, soluble ﬁbers, including
barley, oats, psyllium, and pectin, had no signiﬁcant impacts
on triglyceride concentrations [141]. Other studies have
described hypotriglyceridemic eﬀects of soluble ﬁbers in
various populations. In a study on type 2 diabetic patients,
the intake of a high-soluble ﬁber diet (25g/day) over a
period of 6 weeks lowered triglyceride concentrations by
10.2% [142]. The soluble ﬁber in Plantago Ovata husk re-
duced triglyceridemia in human secondary cardiovascular
disease risk trials, when consumed at 10.5g/day over 8
weeks [143]. Similarly, the consumption of arabinoxylan
at 15g/day over 6 weeks signiﬁcantly reduced postprandial
triglyceride responses in overweight subjects with impaired
glucose tolerance [112]. Discrepancies in ﬁndings could be
attributed to the variability in ﬁber structure, the degree
of solubility and viscosity, diﬀerent administered doses, the
duration of administration, and baseline triglyceride levels
of the subjects.
The eﬀect of β-glucan on lipid parameters has been in-
tensively investigated; however, diﬀering results have been
found. These inconsistencies in ﬁndings may be explained
by several factors including the sources, dose and molecular
size of β-glucans, dietary composition, food preparation,
food state (solid versus liquid), subject’s baseline cholesterol
concentrations, and study design [144] as well as the cultivar
of barley and oat being used and their growing conditions
[145, 146]. Although varied eﬀects of barley and oat-derived
β-glucans have been reported on lipid homeostasis, they
were not established as signiﬁcant diﬀerences since β-glucan
content of these two cereals is almost comparable [147, 148].
In the following sections, the impacts of barley and oat β-
glucans on lipid parameters will be separately discussed.
A limited eﬀect of barley β-glucan on lipid parameters
has been described and the dose of barley β-glucan appears
to be a major determinant of this eﬀect. In a meta-analysis
of randomized clinical trials, the consumption of 3 to 10g
of barley β-glucan per day, over 4 to 6 weeks, signiﬁcantly
lowered total and LDL cholesterol in subjects with diﬀerent
dietary backgrounds [141]. In another meta-analysis of 8
randomized controlled trials, participants receiving 3 to 10g
ofbarleyβ-glucanperday,overadurationrangingbetween4
and 12 weeks, had signiﬁcant reductions in total cholesterol,
LDL cholesterol, and triglycerides in comparison to control
groupparticipants,irrespectiveofwhetheralow-fatoraStep
I diet was given [144]. Moreover, the consumption of pearl
barley, providing 7g of β-glucan per day over 12 weeks, sig-
niﬁcantly reduced serum concentrations of total cholesterol
and LDL cholesterol in hypercholesterolemic Japanese men
[149]. Both total and LDL cholesterol concentrations were
signiﬁcantly reduced following the consumption of the high
barley β-glucan diet (6g/day), in comparison with the diet
low in barley β-glucan (0–0.4g/day) in hypercholesterolemic
subjects [150, 151]. In contrast, daily ingestion of 10g of
barley β-glucan over 4 weeks in the form of bread, cakes,
muﬃns or savory dishes, had no eﬀect on serum lipoprotein
proﬁle in hypercholesterolemic men in comparison with the
control group [152]. In addition, neither 5g nor 10g of bar-
ley β-glucan consumed daily in a beverage over 5 weeks had
a signiﬁcant impact on serum lipids in hypercholesterolemic
subjectsascomparedwithcontrol[121].Thus,inadditionto
dose, the food vehicle delivering barley β-glucan also aﬀects
its regulation of lipid responses.
Despite conﬂicting results, oat β-glucans were found to
be strongly eﬀective in modulating plasma lipid parameters.
As in the case of barley β-glucan, the ingested dose of oat
β-glucan appears as a limiting factor. The US Food and
Drug Administration and Health Canada have accepted
3g as an eﬀective daily intake of oat β-glucan to reduce
serum LDL cholesterol [74, 153]. In a meta-analysis on
oats containing 2 to 10g per day of β-glucan, a net change
of −3.1mg/dL to −15.5mg/dL for total cholesterol and
of −2.9mg/dL to −14.3mg/dL for LDL cholesterol was
observed [55]. A signiﬁcantly greater serum cholesterol
reduction was reported after the intake of 4g of β-glucan
as compared to 2g from oat bran or oat meal incorporated
into muﬃns, cereals, and shakes [154]. Increasing the dose
to 6g of β-glucan did not provide any further reduction
in serum cholesterol concentrations. Similarly, a beverage
providing 5g of β-glucan per day from oats signiﬁcantly
lowered total and LDL cholesterol over a period of 5 weeks
compared to a control beverage, in hypercholesterolemic
individuals [121]. No additional beneﬁt was reported on
serum lipids when increasing the daily dose of oat β-glucan
to 10g. A bread containing 6g of oat-derived β-glucan
signiﬁcantly improved HDL cholesterol and diminished LDL
cholesterol, non-HDL cholesterol, total cholesterol/HDL
cholesterol ratio, and LDL cholesterol/HDL cholesterol ratio,
over 8 weeks compared to whole-wheat bread, in overweight
individuals with mild hypercholesterolemia [155]. Similarly,
the consumption of 6g/day of concentrated oat β-glucan in
the form of powder for 6 weeks signiﬁcantly reduced both
total and LDL cholesterol in hypercholesterolemic adults,
with the reduction in LDL cholesterol being greater than that
in the control group [156]. A once-daily consumption of
4gofβ-glucans from oats, incorporated into a ready-meal
soup, reduced LDL cholesterol levels by 3.7% over 5 weeks
in a group of hyperlipidemic healthy subjects as compared
with a control diet [157]. In contrast, in some studies, the
reductions were small and nonsigniﬁcant, around less than
5% for LDL cholesterol, in comparison to control groups
[158–162]. Food vehicle, rather than dose, seems to explain
such minimal lipid responses to oat β-glucan ingestion in
these studies. A once-daily consumption of 20g of an oat
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of cereal for 12 weeks did not aﬀect total cholesterol and LDL
c h o l e s t e r o la sc o m p a r e dt o2 0gw h e a tb r a n( c o n t r o l )[ 161],
nor did 4 weeks of 5.9g of oat bran β-glucan administered
daily in bread and cookies [162].
The mode of administration of β-glucan is another de-
terminant to consider when explaining such variability in
results since structural changes in β-glucan may result from
food processing or storage of barley and oat products. The
consumption of oat β-glucan in a variety of foods, such
as muﬃns and cereals, eﬀectively lowered LDL cholesterol
[163], suggesting that the structure and molecular weight
of oat β-glucan are maintained in these products. On the
other hand, the eﬀects of oat β-glucan administered in
breadarecontroversial.Theconsumptionofbreadproviding
140g of rolled oats per day led to an 11% reduction in
serumtotalcholesterolconcentrations[164].However,other
studiesfoundnohypocholesterolemiceﬀectofincorporating
oats into bread [158, 165–167]. Bread making can cause
signiﬁcant depolymerization of β-glucan, primarily induced
by β-glucanase enzymes present in wheat ﬂour [162, 168].
The activation of these enzymes depends on the processing
technique used in bread making.
The varied responses of cholesterol-rich lipoproteins to
β-glucanscouldbealsoattributedtodiﬀerencesinmolecular
weight and solubility of the ﬁbers. Molecular weight, solubil-
ity, and viscosity are important physicochemical properties
of β-glucan, which are strongly aﬀected by the genetic
attributes of oat and barley grains [169]. For instance, oat
β-glucans have a higher molecular weight than barley β-
glucans [102, 170–172]. Only 15–20% of barley β-glucans
are water soluble while almost 70% of the oat β-glucans
are soluble in water [173]. Relatively to barley β-glucan,
the higher molecular weight of oat β-glucan is attributed
to a greater content and frequency of side branches rather
than to a higher degree of polymerization, explaining its
higher degree of water solubility [83, 85]. As viscosity is
highly inﬂuenced by the molecular weight and solubility
of β-glucan, a lower molecular weight and/or solubility of
β-glucan are expected to reduce its resultant viscosity and
consequently its cholesterol-lowering eﬀects. Highly water-
soluble β-glucan, with moderate to high molecular weight,
reduced serum LDL cholesterol better than β-glucan with
low water-solubility and low molecular weight [174]. This
explainsthelowerreportedeﬀectsofbarleyβ-glucanonlipid
parameters as compared to oat β-glucan.
The hypocholesterolemic properties of β-glucans are
explained by various mechanisms some of which are shared
with other soluble dietary ﬁbers. Altering bile acid excretion
and the composition of bile acid pool is one of the mech-
anisms. Dietary ﬁbers are associated with increased bile acid
excretionandincreasedactivityofcholesterol7α-hydrolase,a
major enzyme leading to cholesterol elimination in the body
[175]. Beta glucans can decrease the reabsorption of bile
acids and increase their transport towards the large intestine
[176], promoting their increased microbial conversion to
metabolites and their higher excretion, subsequently induc-
ing increased hepatic synthesis of bile acids from circulating
cholesterol [177]. This mechanism is strongly related to
β-glucan-induced increased viscosity in the small intestine
[128, 178, 179] and consequently slowed gastric emptying,
digestion, and absorption [179]. In addition, some soluble
ﬁbers decrease the absorption of dietary cholesterol by
altering the composition of the bile acid pool. In fact, oat
bran increased the portion of total bile acid pool that was
deoxycholic acid [180], a microbial byproduct of bile acid
which decreases the absorption of exogenous cholesterol in
humans [181].
The fermentation of some soluble ﬁbers, including β-
glucan, provides another explanation for their cholesterol-
lowering eﬀects. Fermentation changes the concentration of
bile acids in the intestinal tract of rats [177]a sw e l la st h e
production of short-chain fatty acids, which inﬂuence lipid
metabolism. For example, propionate is thought to suppress
cholesterol synthesis, though results are still inconclusive
[182–186] and acetate may contribute to the lowering
of cholesterol circulating levels [187]. It should be well
noted that diﬀerences between soluble ﬁbers in the relative
production of acetate, propionate, butyrate, and total short-
chain fatty acids do exist. Oat β-glucan ferments more
rapidly than guar gum, reﬂected in higher concentrations
of total short-chain fatty acids, in general, and of acetate
and butyrate, in particular [32]. However, such diﬀerences
may not be that important to generate varied degrees of
hypocholesterolemic impacts among soluble ﬁbers.
Few mechanisms, most not clearly elucidated, have been
suggested in order to explain the hypotriglyceridemic prop-
erties of soluble ﬁbers, including β-glucan. Two mechanisms
include a possible delay in the absorption of triglycerides in
the small intestine [188], as well as a reduced rate of glucose
absorption[189].Glucose-inducedhypertriglyceridemia,via
the process of de novo lipogenesis, is well established in the
literature[190].Furthermore,directinhibitionoflipogenesis
by soluble ﬁbers is also suggested as an explanatory mech-
anism. The hypotriglyceridemic eﬀect of oligofructose was
reported to result from the inhibition of hepatic lipogenesis
via the modulation of fatty acid synthase activity [191, 192].
In an in vitro study, β-glucan extracts from oat and barley
ﬂour inhibited the in vitro intestinal uptake of long-chain
fatty acids and cholesterol and downregulated various genes
involved in lipogenesis and lipid transport in rats [147].
In conclusion, β-glucan possesses similar hypocholes-
terolemic properties as other soluble dietary ﬁbers. However,
the hypotriglyceridemic impacts of β-glucan have not been
fully determined and warrant further investigation. Addi-
tionally, further studies need to be conducted in order to
optimize β-glucan’s hypolipidemic dose and to investigate
the long-term eﬀect of β-glucan supplementation on blood
lipid chemistry. The eventual goal would be to combine β-
glucan supplementation with other dietary means of con-
trolling blood lipids, and to consequently prevent the need
for cholesterol-lowering drugs in hyperlipidemic patients.
3.3.3. Beta Glucan and Blood Pressure. Hypertension is an-
other core component of the metabolic syndrome, and is
an established risk factor for heart diseases, stroke, and renal
diseases [193].
The eﬀects of soluble dietary ﬁbers, including β-glucan,
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the components of the metabolic syndrome. In one meta-
analysis, increased dietary ﬁber consumption provided a
safe and acceptable means to reduce blood pressure in
patients with hypertension [194]. In a randomized crossover
study on hyperlipidemic adults, small reductions in blood
pressure were reported following the intake of a high-ﬁber
diet containing β-glucan or psyllium (8g/day more than the
unsupplementedfoodinthecontroldiet)over4weeks[195].
In another randomized parallel-group study on hypertensive
and hyperinsulinemic men and women, the oat cereal
group (standardized to 5.52g/day of β-glucan) experienced a
signiﬁcant reduction in systolic and diastolic blood pressure
incomparisontothelow-ﬁbercerealcontrolgroup(<1g/day
of total ﬁber) over 6 weeks [196]. Similarly, in a randomized
double-blind placebo-controlled trial on participants with
untreated elevated blood pressure or stage 1 hypertension,
the consumption of 8g/day of supplemented soluble ﬁber
from oat bran over 12 weeks signiﬁcantly reduced both
systolic and diastolic blood pressure in comparison to the
control [197].
Various mechanisms underlying the antihypertensive ef-
fects of soluble dietary ﬁbers have been hypothesized. In-
sulin resistance is a major underlying mechanism contribut-
ing to the development of hypertension [198] and sol-
uble ﬁbers may aﬀect blood pressure by modulating in-
sulin metabolism [199]. Reductions in plasma cholesterol,
observed following the ingestion of soluble ﬁbers, are also
associated with improvements in endothelium-mediated
vasodilation [200, 201]. Preliminary ﬁndings in animals
support a direct relationship between changes in circulating
c h o l e s t e r o ll e v e l sa n db l o o dp r e s s u r e[ 202]. Finally, soluble
ﬁber-induced weight loss, which will be discussed in the
coming section, has also been suggested as a potential
mechanism. Increased body weight is a strong risk factor for
hypertension [203].
In conclusion, additional studies are still needed in order
to fully elucidate the mechanisms underlying the protective
eﬀects of soluble ﬁbers against hypertension. Moreover, the
association between β-glucan and blood pressure remains to
be further explored.
3.3.4. Beta Glucan, Satiety, and Obesity. Central obesity is a
well-established component of the metabolic syndrome [3].
One potential countermeasure to the current obesity ep-
idemic is to identify and recommend foods that sponta-
neously reduce energy intake by inducing satiation and in-
creasing satiety.
Dietary ﬁber has documented eﬀects on satiety, food
intake, and body weight although the outcomes have not
been consistent [204]. A number of randomized controlled
trials have shown weight reduction with diets rich in dietary
ﬁber or dietary ﬁber supplements [205–208], while others
have not [209]. However, a meta-analysis of 22 clinical
trials concluded that a 12g increase in daily ﬁber intake is
associatedwitha10%reductioninenergyintakeanda1.9kg
reduction in weight during an average study duration of
3.8 months [204]. More speciﬁcally, the soluble dietary ﬁber
glucomannan, which has a strong water-holding capacity,
resulted in a signiﬁcantly greater reduction of weight, when
consumed at a dose of 1.24g daily for 5 weeks in conjunction
with an energy-restricted diet, as compared to the placebo
energy-restricted group [210].
Despite the clear association between soluble ﬁbers and
weight loss, their eﬀects on subjective measures of satiety
are not conclusive. However, soluble ﬁbers with viscosity-
producing properties, including guar gum, pectin, psyllium,
and β-glucan, are more strongly associated with reduced
hunger and/or appetite perceptions than low/no ﬁber condi-
tion [211]. For example, the addition of 2.5g of guar gum to
a semisolid meal prevented an increase in appetite, hunger,
and desire to eat in overweight male volunteers [212]. The
soluble resistant dextrins promoted, in a dose-dependent
manner, increased satiety when added to desserts and to
carbohydrate-based meals [213–215]. Moreover, a nutrition
bar containing guar gum (5.7g guar gum and 9.1g other
ﬁbers) increased perceived fullness and decreased hunger
sensationsascomparedtoareferencebar(6.4g dietary ﬁber)
[216].
B a r l e y ,as o u r c eo fβ-glucan, possesses satiating proper-
ties when fed intact. Subjects described to be signiﬁcantly
less hungry before lunch after consuming barley—but not
wheat—and rice-containing foods [217]. Barley-based foods
enhanced as well satiety when compared to a high-glycemic
index food or a food with no dietary ﬁber [218–220]. This
eﬀect does not appear speciﬁc to one type of barley, as
diﬀerent cultivars of barley produced an equivalently greater
satiety feeling, up to 180min postprandially, in comparison
to white wheat bread [218].
In contrast to whole barley, both positive [128, 221–
223] and negative [220, 224–226]e ﬀects of β-glucan on
satiety have been described. A beverage containing oat
β-glucan, at levels of 10.5g/400g portion and 2.5g and
5g/300g portion, increased fullness sensation in comparison
to the beverage free of ﬁber in healthy volunteers [222,
227]. Similarly, a preload of 5.2% barley β-glucan-enriched
biscuits signiﬁcantly suppressed appetite ratings in healthy
adolescents, without modifying subsequent food intake at
lunch, as compared with control biscuits [228]. In healthy
participants, a 3% barley β-glucan-enriched bread induced
a higher reduction of hunger and increase in fullness and
satiety as compared to the control bread. This was also
associated with a signiﬁcant reduction of energy intake at
the subsequent lunch [223]. In contrast, a meal replacement
bar containing 1.2g of barley β-glucan (from 8.0g barley),
consumed at breakfast on 2 consecutive days by healthy
subjects, did not modify appetite scores or energy intake at
subsequent lunch in comparison to a control bar containing
only 0.3g β-glucan (from 6.8g oats) [226]. Moreover, muesli
containing 4g of oat β-glucan did not induce diﬀerential
satiating eﬀects than an isocaloric portion of cornﬂakes in
healthy individuals [123], as a dose of 2g of β-glucan in
cereal test meals did not aﬀect satiety ratings in comparison
to isocaloric glucose load in overweight participants [225].
The eﬃcacy of β-glucan on satiety depends on several
factors. Dose is one of the major determinants. A beverage
(300g) containing 5g of oat dietary ﬁber (2.5g of β-glucan)
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ﬁber-free beverage [227]. However, when the dose was raised
to 10g of oat ﬁber (5g of β-glucan), no additional impact on
satiety scores was reported [227]. The physical eﬀects of β-
glucansontheingestaappeartobefundamentallyimportant
in shaping their satiating properties. This eﬀect is largely
determined by molecular size and solubility of β-glucans
[229]. The molecular weight of β-glucan, a major determi-
nant of solubility, varies from 31 to 3100 kilodaltons [230]
and can change during isolation, puriﬁcation, and extraction
procedures [231]. Such variability in the molecular weight
and solubility of β-glucan may explain its varied impacts on
satiety. Finally, the carrier food also plays a role in deﬁning
the interaction of β-glucans with satiety. Almost all studies
that did not report any signiﬁcant inﬂuence of β-glucan
on satiety used solid or semisolid foods as carrier foods,
unlike studies that incorporated β-glucan into liquid meals
[227]. Solid foods are known to increase satiety and decrease
hunger more eﬀe c t i v e l yt h a nl i q u i do n e s[ 232]. Thus, the
larger satiating eﬀect of solid food per se may mask the
satiating potential of β-glucans.
Since almost all studies did not account for these fac-
tors and were run under diﬀerent experimental conditions
(diﬀerentβ-glucandose,variousmolecularweightsandfood
sources of the ﬁber, diﬀerent dosing protocols, and diverse
types of subjects), ranking the satiating power of β-glucan is
still not possible at this stage. Moreover, another concern to
be addressed in future studies is the type of control to use.
No dietary ﬁber that may function as a control for satiety
studies has been actually identiﬁed. In almost all studies, the
control food was the same food with either a lower amount
or a complete absence of β-glucans.
As the eﬀect of β-glucan on satiety is still unclear, its
eﬀect on body weight regulation is less clear. In a study
on diabetic patients, the supplementation of β-glucan from
oats, at a dose of 9g/day over 24 weeks, did not have
any signiﬁcant eﬀect on body weight [69, 233]. In another
study on hyperlipidemic patients, weight diﬀerences were
not observed following the consumption of a diet rich in
oat β-glucan (8g/day), over 1 month, as compared to the
control group [195]. It should be noted that the body
weight was not the primary concern of these studies as
they focused on changes in blood sugar or blood lipids.
Even at moderate (5-6g/d) and high (8-9g/d) doses, the
addition of oat β-glucan to an energy-restricted diet did
not enhance the eﬀect of energy restriction on weight loss
in overweight women after a period of 3 months [234]. In
contrast, hypercholesterolemic Japanese men consuming a
m i x t u r eo fri c ea n dp e a r lb a r l eywi t hah i ghβ-glucan content
(7g/day), for 12 weeks, experienced a signiﬁcant reduction
in body mass index, waist circumference, and visceral fat
in comparison to the placebo group consuming rice alone
[149]. Variations in the food sources of β-glucan, rather
than in the dose and the duration of administration, may
explain such contradictions in ﬁndings and appear as critical
determinants of body weight regulation.
The satiating properties of soluble dietary ﬁbers have
been explained by various mechanisms, all of which are
related to several stages in the process of appetite regula-
tion such as taste, gastric emptying, absorption, and fer-
mentation [235]. Firstly, the viscosity of soluble ﬁbers plays
an important role in their ability to induce satiety [222,
236, 237]. The most viscous β-glucan-enriched beverage
increased perceived satiety signiﬁcantly more than the
beverage containing the same amount of ﬁber but with
enzymatically lowered viscosity [227]. A higher viscosity
meal delays gastric emptying [130, 131, 238] and slows
the digestion and absorption of nutrients, more precisely
glucose, due to reduced enzymatic activity and mucosal
absorption [31, 239], leading to early satiety sensations.
The overall gastric emptying rate of healthy volunteers, as
assessed by the paracetamol absorption test, was slower after
thehighviscosityoatbran-enrichedbeverageascomparedto
the low viscosity drink [240]. Secondly, the lower palatability
of ﬁber-rich meals may aﬀect food intake in a negative
manner [241–243]. A strong inverse relationship is described
between palatability and satiation [244]. When chronically
consumed, products enriched with β-glucan had lower
sensory acceptance [121, 245]. Third, the reduced glycemic
and insulinemic responses to soluble ﬁbers, including β-
glucan, can be also responsible for their satiating properties.
A signiﬁcant inverse relationship is reported between satiety
and glucose and insulin responses to carbohydrate-rich
breakfast cereals [246, 247] and to beverages with diﬀerent
glycemic eﬀects [248]. However, other studies did not report
any association of glucose and insulin postprandial levels
with satiety [249, 250]. They suggested that the release
of putative satiety peptides is a more crucial component
of mechanisms initiating and maintaining satiety. Such
statement leads to the fourth suggested mechanism that
delineates the role of short-chain fatty acids in appetite
control.Short-chainfattyacidsregulatethereleaseofvarious
gut hormones, which play an important role in satiety
signaling. Most β-glucan consumed is fermented in the
caecum and colon, producing short-chain fatty acids [79].
The role of short-chain fatty acids in appetite regulation and
the potential underlying mechanisms will be elucidated in
the following sections.
(i) Short-Chain Fatty Acids and Appetite Regulation. Dietary
ﬁ b e r sp a s sa su n a ﬀected through the small intestine, and
upon reaching the colon, anaerobic bacteria degrade some
dietary ﬁbers via a fermentation process, yielding short-
chain fatty acids. The fermentability of soluble ﬁbers by
colonic microbiota is greater than that of insoluble ﬁbers.
Pectin, resistant starches, gums, and polyfructans (such as
inulin) are the most highly fermented substrates. Around
80% of short-chain fatty acids present in the human colonic
lumen are in the form of acetate, propionate, and butyrate
[251]. About 90% of these short-chain fatty acids are rapidly
absorbed in the colon; butyrate is almost entirely used by
the colonocytes as their preferred energy substrates [252]
while propionate is primarily removed by the liver [251].
On the other hand, acetate passes more freely into the
peripheral circulation [253]. Several functions are attributed
to short-chain fatty acids, being recently proposed as key
energy homeostasis signaling molecules [254].
Accumulatingevidencehasattributedthesatiatingeﬀects
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major fermentation products [255]. Short-chain fatty acids
regulate appetite through several mechanisms. First, short-
chain fatty acids have a role in slowing gastrointestinal mo-
tility, thus controlling digestion and nutrient absorption
and eliciting an anorexigenic eﬀect. The majority of the
studieslinking short-chainfatty acidstogastrointestinalmo-
tility stems from ruminant animal studies [256], where the
production of short-chain fatty acids is greater than that in
humans due to diﬀerences in gut physiology [257]. However,
there are some studies on nonruminants showing that short-
chain fatty acids may regulate the overall transit time of the
digestathroughthelargeintestine[258,259].Suchresponses
were hypothesized to occur via three possible pathways: (1)
short-chain fatty acid stimulation of the vagal nerves in the
gut, (2) a direct eﬀect of short-chain fatty acids on intestinal
smooth muscle tone, and (3) as a consequence of the indirect
changes in the secretion of peptide YY (PYY) and other
regulatory peptides known to play a role in gastrointestinal
motility [260]. In addition, short-chain fatty acids were
suggested to regulate gastrointestinal motility by aﬀecting
the release of the gastrointestinal 5-hydroxytryptamine (5-
HT) via the activation of the free fatty acid receptor 2
(FFA2), the major receptor for short-chain fatty acids. 5-
HT or serotonin is a neurotransmitter in the central nerv-
ous system, known to modulate mood, behavior, and ap-
petite [261]. Though the central actions of 5-HT are the
most documented, 95% of endogenous 5-HT is found
peripherallyinthegastrointestinaltract[262].Theactivation
of various 5-HT receptor subtypes stimulates vagal nodose
neurons and consequently prolongs colonic transit time
[263, 264]. Short-chain fatty acids also regulate appetite by
modulating the release of various appetite-related hormones
throughout the gastrointestinal tract [265]. The eﬀects of
short-chain fatty acids on the release of some of these gut
hormones, including PYY, glucagon-like peptide 1 (GLP-
1), cholecystokinin (CCK), and ghrelin, will be discussed in
the following sections, providing partial explanations for the
reported impacts of soluble dietary ﬁbers in general, and of
β-glucan speciﬁcally, on satiety hormones and consequently
on appetite and food intake.
Peptide YY. Peptide YY is a 36-amino acid peptide, ﬁrst
isolated from porcine upper small intestine [266]. Two cir-
culating forms of PYY are released by L cells in the dis-
tal gut, PYY1–36 and PYY3–36, which is the truncated major
circulating form [267]. PYY is secreted throughout the entire
length of the gastrointestinal tract, with the highest concen-
trations found in the colon and rectum [268]. Circulating
PYY levels are the lowest in the fasting state and increase
following the consumption of a meal, peaking at 1-2 hours
and remaining elevated for several hours. Peripheral PYY
administration decreased food intake and body weight gain
in rats [269]. Similarly, it decreased appetite and food intake
both in lean and obese humans [269, 270].
An increased PYY response was consistently described
following the consumption of various soluble dietary ﬁbers.
Postprandial PYY clearly increased after the consumption
of psyllium-enriched test meals in healthy volunteers [271].
The consumption of PolyGlycopleX, a novel functional ﬁber
complex manufactured from three dietary ﬁbers to form a
highly viscous polysaccharide with high water-holding and
gel-forming properties, for 3 weeks resulted in signiﬁcantly
increased fasting PYY levels as compared to the control
product in healthy adults [272]. Moreover, a meal tolerance
test in overweight and obese adults consuming 21g of
oligofructose for 3 months resulted in a greater increase in
PYY concentrations as compared to the placebo group, con-
comitant with a reduced self-reported caloric intake [273].
The ability of β-glucan to increase PYY release was
reported in various population groups. In healthy subjects,
bread enriched with 3g barley β-glucans induced a 16%
higher overall PYY response in comparison to the control
bread [223]. Even in overweight men and women, PYY levels
responded positively and in a dose-responsive manner to
increasing oat β-glucan concentrations, ranging from 2.16g
to 5.45g per serving, in the ﬁrst 4 hours after a meal [274].
The fermentation process of β-glucan and the subse-
quent generation of short-chain fatty acids provide a major
explanatory mechanism for β-glucan-induced PYY release.
The direct infusion of short-chain fatty acids into rabbit
and rat colons signiﬁcantly increased PYY secretions [275,
276]. The stimulatory eﬀects of short-chain fatty acids on
PYY secretions are mainly attributed to a direct interaction
between short-chain fatty acids and PYY cells. In fact, FFA2
(also known as GPR43), the major receptor for short-
chain fatty acids, is colocalized with PYY immunoreactive
enteroendocrine L cells both in rat ileum and human colon
[259, 277].
Glucagon-Like Peptide 1. Glucagon-like peptide 1 is cose-
creted with PYY from the intestinal L cells, encoded by the
proglucagongene[278].Itisdescribedwithapotentincretin
eﬀect, stimulating insulin secretion in a glucose-dependent
manner. Circulating GLP-1 levels rise following nutrient
ingestion, in proportion to the energetic content of the meal
[279]. An acute intracerebroventricular administration of
GLP-1 to rodents induced a decline in short-term energy
intake [280], and was associated with a reduced body
weightfollowingrepeatedadministration[281].Similarly,an
intravenous infusion of GLP-1 both in normal weight and
in obese subjects resulted in a dose-dependent reduction in
food intake [282].
The eﬀects of β-glucan on GLP-1 release have not been
yet elucidated; however, the eﬀects of other soluble ﬁbers
have been investigated. Variable GLP-1 responses to soluble
dietary ﬁber intake were described, whether elevated, inhib-
ited,orunaﬀected.Theexposuretoadietsupplementedwith
10% oligofructose for 4 weeks increased the number of GLP-
1 - p r o d u c i n gL - c e ll sa sw e lla se n d o g e n o u sG L P - 1p r o d u cti o n
in the proximal colon of male Wistar rats in comparison
to a standard diet [283]. In humans, a standard breakfast
containing galactose (50g) and guar gum (2.5g) increased,
extendedly, GLP-1 release in healthy women as compared
with a standard control breakfast [284]. In contrast, in
normal-weight males, resistant (pregelatinized) starch (50g)
produced a smaller GLP-1 response than digestible starch
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enriched with a small amount of psyllium ﬁber (1.7g) did
not modify postprandial GLP-1 responses in comparison to
the control pasta in healthy subjects [286]. Such discrepan-
ciesinﬁndingscouldbeattributedtodiﬀerencesinthestruc-
turesandfoodsourcesofingestedsolubleﬁbersandtheirad-
ministered doses.
Colonic fermentation appears to be essential in explain-
ing GLP-1 release in response to soluble dietary ﬁbers,
despite inconsistent ﬁndings. Though supplementation with
fermentable carbohydrates has been consistently associated
with increased colonic proglucagon mRNA expression [287–
293], only few studies detected increased plasma GLP-
1 circulating levels in parallel [288–290, 293–295]. Rats
fed high doses of the fermentable inulin-type fructans
(100g/day), over 3 weeks, had higher mRNA expressions
in the proximal colon and plasma concentrations of GLP-
1 as compared to those fed a standard diet [288]. The
exposure of male Wistar rats to a diet supplemented with
10% of inulin-type fructans, for 3 weeks, resulted in a
higher caecal pool of GLP-1, an increase in GLP-1 and
of its precursor proglucagon mRNA concentrations in the
proximal colon, and an increase in the circulating levels of
GLP-1 as compared to the standard diet [289]. In normal-
weight adults, the microbial fermentation of 16g of soluble
fructan per day, over 2 weeks, induced increased levels of
GLP-1 in circulation as compared to the control dextrin
maltose [296]. A strong association between postprandial
hydrogen production and plasma GLP-1 concentrations
was also reported. On the contrary, others have shown
no eﬀect of fermentable carbohydrates on circulating GLP-
1 levels, whether acutely [297] or over a short duration
of 6 days [298]. Based on these ﬁndings, the duration of
supplementation is an important factor to consider when
suggesting fermentation as a basis for soluble ﬁbers-induced
GLP-1 release. A suﬃcient time of 2-3 weeks must be
given in order to allow adaptation of the gut microbiota to
the additional fermentable carbohydrate within the diet for
maximal fermentation to take place [299]a n df o rG L P - 1
levels in circulation to be subsequently aﬀected.
Cholecystokinin. Cholecystokinin was among the ﬁrst hor-
mones shown to modulate food intake [300]. It is secreted
from the I cells of the small intestine in response to
food ingestion [301]. Cholecystokinin circulating levels rise
rapidlyafterameal,reachingapeakwithin15minutes.Itwas
found to reduce food intake when infused both in rodents
and humans [301, 302]. In fact, plasma CCK levels are
strongly associated with subjective measurements of satiety
in women [303].
Limitedstudiesdescribedtheinteractionbetweensoluble
dietary ﬁbers and CCK release. Various soluble ﬁbers, in-
cluding hydrolyzed guar gum (20g) in obese females [304],
β-glucan in barley pasta (15.7g) in healthy men [128], and
isolated ﬁbers from oatmeal and oat bran (8.6g) in healthy
men [305], produced greater and longer-lasting postprandial
CCK levels in comparison to low-ﬁber or placebo meals.
A study on overweight women revealed a dose-dependent
eﬀectofincreasedoatβ-glucanconcentrations,rangingfrom
2.16 to 5.68g per serving, on CCK levels in the ﬁrst 4 hours
after a meal, with a signiﬁcant CCK release observed at a
minimum dose of 3.8g of β-glucan [127].
The role of fermentation and more speciﬁcally short-
chain fatty acids in regulating CCK release is still poorly
understood. In pigs, ileal infusion of short-chain fatty acids
did not aﬀect CCK circulating levels [306]. Thus, the
fermentation process per se does not explain CCK responses
to β-glucan ingestion. Additional mechanisms underlying
thestimulatoryeﬀectsofβ-glucanonCCKsecretionsremain
to be explored.
Ghrelin. Ghrelin is the only known orexigenic hormone in
the gut. It was initially identiﬁed as an endogenous ligand
for growth hormone secretagogue receptor (GH-SR) in rat
stomach [307]. Circulating ghrelin levels increase before
meals and fall rapidly after eating [308]. Both central and
peripheral administration of ghrelin increased food intake
and body weight in rodents [309, 310].
The eﬀects of soluble ﬁbers, including β-glucan, on post-
prandial ghrelin are not fully understood. The consumption
of a small amount (4g) of noncaloric soluble psyllium ﬁ-
ber with water suppressed postprandial ghrelin levels as ef-
fectively as a 585-Kcal mixed meal in healthy women [311].
On the other hand, postprandial plasma ghrelin did not
decrease following gastric distention with a noncaloric liq-
uid meal containing 21g of soluble guar gum ﬁber in com-
parison to carbohydrate-, protein-, and fat-rich meals [312].
Moreover, a 300-Kcal meal enriched with 23g of psyllium
ﬁber inhibited postprandial suppression of plasma ghrelin
levels [313]. When compared to a control breakfast, a soluble
arabinoxylan ﬁber-enriched breakfast (6g) induced a shorter
postprandial ghrelin decline [314] whereas bread enriched
with 3g barley β-glucans resulted in 23% lower ghrelin
responses than a control bread [223]. Discrepancies in
ﬁndings could be explained by variations in the physical and
chemical properties of ingested soluble ﬁbers, their diﬀerent
administered doses, andtheformsofghrelinbeing measured
in circulation.
Several mechanisms were suggested to explain ﬁber-
induced ghrelin suppression, most importantly fermenta-
tion. Feeding a diet supplemented with 10% of the fer-
mentable inulin to rats over 3 weeks signiﬁcantly reduced
ghrelin levels in comparison to a standard diet [289]. The
ingestion of 56g of high-fructose corn syrup (HFCS) plus
24g inulin induced greater postprandial ghrelin suppression
as compared to HFCS without inulin, both at 4.5 and 6
hours, in healthy subjects [315]. Such colonic fermentation
may reduce ghrelin via increasing circulating PYY levels.
Administration of PYY to humans reduced serum ghrelin
levels [316]. In addition to colonic fermentation, other
mechanisms were also hypothesized. A possible inner-gastric
pathway may operate through gastric somatostatin, which is
released following the consumption of beet ﬁber in diabetic
individuals [317]. Somatostatin administration decreased
ghrelin secretion in rats [318] and lowered circulating ghrel-
in levels in humans [319]. In addition, GLP-1 release in res-
ponse to soluble ﬁbers is another potential mechanism. In-
fusion of GLP-1 into isolated rat stomach suppressed ghrelin
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In conclusion, there is evidence for the satiety eﬃcacy of
β-glucan. Such satiating capacity appears to be comparable
to that of other soluble viscous and fermentable ﬁbers. Al-
though several mechanisms may explain the satiating prop-
erties of β-glucan, the generation of short-chain fatty acids
through colonic fermentation has the most documented
eﬀects. Short-chain fatty acids aﬀect satiety by primarily
modulating the release of various appetite-regulating hor-
mones, including PYY, GLP-1, and ghrelin. However, other
yet unknown mechanisms, independent of short-chain fatty
acids, may be involved in the regulation of gut hormones
by β-glucans. Since research in this area is still limited, such
mechanisms necessitate further investigation. Combining
knowledge from previous studies, a minimum level of β-
glucan, ranging from 4 to 6g, appears to be essential for its
gastrointestinal appetite-regulating eﬀects [321]. However,
additional studies addressing the role of dose, form, mol-
ecular weight and carrier food on the interaction bet-
ween β-glucan and satiety are still needed before drawing
solid conclusions. Moreover, the role of β-glucan in long-
term weight regulation is still not well understood and needs
to be further explored. Inconsistencies in data regarding the
eﬀect of dietary or supplementary β-glucan on body weight
highlight the need for additional research.
4.Beta Glucan-FortiﬁedFoods inthe Market
4.1.GlobalDietaryFiberIntake. Insuﬃcientintakeofdietary
ﬁberhasbeen reported worldwide. However, the estimates of
ﬁber intake are highly variable.
In the United States, dietary ﬁber intake was calculated
to be 17g for males and 12.8g for females based on the
NHANES III study [322]. Based on the results of the Na-
tionwide Food Consumption Survey, a mean dietary ﬁber
intake of 11.4g per day was reported [323]. Similarly, a
mean daily ﬁber intake of 13.7g in total, comprising 4.2g
of water-soluble ﬁber and 6.8g of water-insoluble ﬁber,
was described based on the Multiple Risk Factor Interven-
tion Trial [324]. In contrast, Hallfrisch et al. [325]a n d
Hermann et al. [326] reported higher intake values, av-
eraging 15g/day and 18.3g/day, respectively. Regardless,
intakes of dietary ﬁbers in the American population are
below levels recommended by the Institute of Medicine (38g
for males and 25g for females).
In Canada, low daily dietary ﬁber intakes have been also
noted. According to Nova Scotia Department of Health
[327], the mean dietary ﬁber intake was estimated to be
13.5g per day, ranging from 9.6g (young women) to 17g
(elderly men). The main sources (88%) of ﬁber in the diet
werereportedtobepasta,rice,cerealsandbreads,vegetables,
fruits, and fruit juices [327]. Similarly, in a more recent study
onhealthyCanadianadolescentmales,amediandietaryﬁber
intake of 13.1g per day was observed [328].
In Europe, the estimated national values for dietary ﬁber
intake were found to fall within a narrower range: 16g/day in
France [329], 22.1g/day in Sweden [330], 16.7–20.1g/day in
Finland [331], 21g/day in Germany [332], and 20–22g/day
in the Netherlands [333]. An exceptionally high intake level
of ﬁber was found in Switzerland, 30–33g/day, reﬂecting a
positive trend in the eating habits of this population [334].
In the United Kingdom, lower values of 14–16g/day for men
and 18-19g/day for women were reported [335].
Thus, ﬁber intakes worldwide are well below the recom-
mendedlevelsdespitetherecommendationsofseveralhealth
organizationstoincreasetheconsumptionoffoodswithhigh
ﬁber content.
4.2. Beta Glucan in Functional Foods. The introduction of
ﬁber into traditional and processed foods provides one
method by which to increase ﬁber intake [81]. Based on
consumers’ demands for healthier options, the food industry
has aimed at developing new products towards functional
foods and ingredients.
The best-known examples of functional foods are fer-
mented milks and yoghurts. Several ﬁber-fortiﬁed dairy
products are now appearing in market, with inulin being a
popular ﬁber source for such products due to its combined
nutritional and technological characteristics [336–341].
Beta glucan is commonly used as a functional ingredient
in foods as it is readily available as a byproduct of oat and
barley milling and it also provides physiological beneﬁts
that are supported by health claims in many jurisdictions.
This polysaccharide is also used as a food ingredient in
the form of hydrocolloids [342, 343]o ra sp o w d e ru s i n g
microparticulation [344]. The addition of β-glucan into
various products, such as baking products, muﬃns, cakes,
pasta, noodles, muesli cereals, milk products, soups, salad
dressings, beverages, and reduced-fat dairy and meat prod-
ucts, was found to aﬀect their attributes, including bread
makingperformance,waterbindingandemulsionstabilizing
capacity, thickening ability, texture and appearance, in a
concentration-, molecular weight-, and structure-dependent
manner [22, 345, 346]. Besides enhancing the nutritional
value, β-glucans can improve the sensory and gustatory
properties of some products. However, the stability of the
physiological properties of β-glucan when extracted and
added to foods has received little examination, leaving un-
certain the health beneﬁts of β-glucan when incorporated
into foods.
In the following sections, the chemical and physiologic
functionality of β-glucans in food preparations is discussed.
4.2.1. Breakfast Cereals. Oats have been frequently used as
an additive in the preparation of cereal products, decreasing
water activity and subsequently prolonging durability [81].
Several oat-based breakfast cereals have experienced great
success in the market. Adding 20% oat β-glucan into choco-
late breakfast ﬂakes protected the viability and stabilized the
cells of lactobacillus rhamnosus, a gut-friendly probiotic bac-
teria, at temperatures higher than 20◦C[ 347]. As breakfast
cereals are commonly consumed in North America, several
oat-based hot and cold breakfast cereals are available in the
market, making use of β-glucan’s approved health claims.
These products are readily accepted by consumers.
4.2.2.BakingProducts. Theincorporationofoatsintobaking
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been widely tested [81]. The incorporation of β-glucans to
baking products seems promising, ameliorating both sen-
sory characteristics and health properties of products at a
maximum concentration of 20%. When oat ﬂour has been
substituted for 10% of ﬁne wheat ﬂour in bread, product
quality improved in terms of crust color, bread softness, and
taste [348] .M o r e o v e r ,ap o s i t i v ee ﬀect of oat β-glucan on the
sensorial characteristics of biscuits has been described [343].
The addition of the hydrocolloids Nutrim O-B (10% β-
glucan) and C-Trim-20 (20% β-glucan) increased the taste,
moisture, and adhesiveness of the product. Similarly, an
oat component called Nutrim-5, a hydrocolloid preparation
of β-glucans produced by treating oat grain or ﬂour with
a thermal process, improved the overall strength of pasta
without negatively aﬀecting either the quality or the sensory
properties [349].
4.2.3. Milk Products. Oats are also used as additives in the
production of yogurts with increased amount of ﬁber [81].
Fiber addition increased the solidity ratio and texture of
unsweetened yogurts, accelerated their acidiﬁcation rate,
and increased their viscosity [350]. When substituting fat
with β-glucans hydrocolloid component at 3.47% and 6.8%
in low-fat cheddar cheeses, a softer texture was described
with decreased melting time and lowered sensory properties
[351]. The addition of oat β-glucans concentrate, at 0.7%
and 1.4% w/w, to white low-fat cheese products in salt
brine improved product texture, while unfavorably aﬀecting
its appearance, taste, and odor when compared with the
control samples [352]. The probiotic eﬀect of β-glucans
has been also studied. Beta glucans selectively support the
growth of Lactobacilli and Biﬁdobacteria, both of them being
antagonists to pathogenic bacteria in the digestive system
[12, 173]. The addition of oat β-glucans to probiotic milk-
baseddrinks, atdosesof0.31–0.36%, increasedtheirstability
along with their health beneﬁts [353].
The eﬀects of β- g l u c a no nm i l ks e n s o r i a lp r o p e r t i e s
have been reported, but results are variable [56, 121, 245,
354]. Oat milk containing β-glucan (0.5g/100g) was well
perceived and got similar sensory evaluation as the control
drink (<0.02g β-glucan/100g) [56]. Sensory evaluations
were higherfor the milk beverage(500mL) enriched with 5g
as compared to the one enriched with 10g of oat and barley
β-glucan [121]. However, milk enriched with 5g β-glucan
had similar sensorial characteristics to the control drink.
In conclusion, the addition of β-glucansto yogurts seems
to impair their sensory qualities despite improving other
rheological properties, irrespective of the dose. On the other
hand, addition of β-glucans to milk, at doses not exceeding
1%, may provide health beneﬁts without compromising
sensorial attributes.
4.2.4. Meat Products. Due to its ability to mimic fat char-
acteristics, oat ﬁber is one of the most eﬀective ingredients
in making low-fat meat products. It can be used to oﬀset
the poor quality associated with low-fat beef burgers [355]
as well as low-fat sausages [356]. There is no speciﬁc stu-
dy investigating the eﬀect of β-glucan, as a fat replacer, on
the sensorial attributes and rheological properties of meat
products. Thus, future studies should address this applica-
bility option of β-glucan.
In conclusion, the introduction of β-glucans into food
preparations has both beneﬁcial and deleterious impacts.
Such impacts mainly depend on the food product to which
β-glucan is added, in addition to the source, the form, and
the dose of β-glucan in use. Alterations in the sensorial
properties and physiochemical attributes induced by β-
glucan may be desirable for some products while being
detrimental for others.
4.3.ChallengesofBetaGlucanFortiﬁcation. Oneofthemajor
challenges faced by the functional food industry is develop-
ing functional foods with an acceptable taste to the average
consumer [357]. Incorporating signiﬁcant quantities of ﬁber
into food products constitutes a technological challenge
due to the possible deleterious eﬀects on textural quality.
The addition of ﬁbers may contribute to modiﬁcations in
the texture, sensory characteristics, and shelf-life of foods
due to their water-binding capacity, gel-forming ability, fat
mimetic, antisticking, anticlumping, texturising, and thick-
ening eﬀects [358, 359].
Adding β-glucan into milk and dairy products was re-
ported to be problematic; ﬁrst due to its viscosity that may
alter the sensory characteristic of foods and second due
to its typical slimy texture in the mouth [100]. However,
the acceptance rate does not seem to be inﬂuenced by the
amount of β-glucan added to test products but rather by
thedurationofconsumptionoftheseproducts.Blackcurrant
ﬂavoredoatmilk(0.5gβ-glucan/100g)waswelllikedamong
volunteers without diﬀerencing it from its counterpart, a
rice beverage with the same ﬂavor (<0.02g β-glucan/100g),
at a single evaluation [56]. In addition, the sensory quality
of a ﬂavored oat-based fermented product (containing
0.6% β-glucan) was acceptable, in comparison to ﬂavored
commercial yogurt or nondairy products, in one single taste
test [354]. In contrast, when consumed over 5 weeks, oat-
based fermented dairy products (0.5-0.6% β-glucan) were
less preferred than fermented dairy-based control products
(<0.05% β-glucan)[245].Similarly,afteraperiodof5weeks,
beverageswith10gofbarleyoroatβ-glucanwereratedlower
than those with 5g of barley or oat β-glucan [121]. These
ﬁndings reﬂect that, when chronically consumed, β-glucan
may impair the sensorial perceptions of foods.
Thus, the development of β-glucan-fortiﬁed foods
remains highly challenging as consumers are not willing to
accept greater health beneﬁts on the expense of deteriora-
tions in the sensory characteristics of food products.
4.4. Eﬀects of Food Processing on the Biological Activities of β-
Glucan. Food processing alters the physical, chemical, and
physiologic characteristics of dietary ﬁbers. Several pro-
cessing techniques, including cooking, freezing, and storing,
aﬀect the physicochemical characteristics of β-glucan. Both
molecular weight and extractability are important compo-
nents of the physiological activity of β-glucan and both can
be aﬀected by food processing [360]. The molecular weight16 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
of β-glucan in processed oat foods can be smaller than
unprocessed. Solubility, which is related to extractability,
typically increases initially with processing as depolymeri-
sation occurs and β-glucan is released from the cell wall;
however, as this degradation continues, solubility decreases
as insoluble β-glucan aggregates are formed [361]. In pro-
ducts such as oat porridge and oat granola, there is little
eﬀectofprocessingonβ-glucanmolecularweight[172,362].
However, the molecular weight of β-glucan in products such
as oat crisp bread decreases by 92% compared to its original
oat source [362]. Other studies have also seen reductions in
molecular weight in similar products made from diﬀerent
grains [168, 172, 363] and attributed these reductions in
molecular weight to the eﬀects of β-glucanase enzymes in
wheat ﬂour used to make these products [168, 172, 364–
366]. These reductions in molecular weight increase with the
mixing and fermentation time of the dough [172]. Freezing
was also found to aﬀect β-glucan solubility. Frozen storage
of oat bran muﬃns signiﬁcantly lowered β-glucan solubility
over time, using in vitro extraction simulating human
digestion [231]. In addition, freeze-thaw cycle reduced the
solubility of β-glucan in oat bran muﬃns by 9% to 55% of
the fresh values.
Whether such physicochemical alterations induced by
food processing have a signiﬁcant impact on the established
health properties of β-glucan is not clear. Eﬀectiveness of
β-glucan in modulating glucose and insulin parameters is
related to dose and viscosity, which can be altered during
processing[74].Infact,85%ofthevariationinbloodglucose
concentrations is explained by the amount of β-glucan
solubilizedandnotthetotalamountoriginallyaddedtofood
[367]. On the other hand, the role of viscosity, molecular
weight, and solubility, susceptible to modiﬁcations by food
processing,inregulatingβ-glucan’seﬀectoncholesterolmet-
abolism has not been demonstrated and requires further
investigation [74].
Thus, since physiologic eﬀects of β-glucans may be al-
tered by food processing, it is important to develop a further
understanding of such an interaction.
5. Summary and Conclusion
It is clear that β-glucan is an important food component in
the modulation of metabolic dysregulations associated with
the metabolic syndrome. However, dose, form, molecular
weight, and the carrier food of β-glucan shape its eﬀect.
The physiological eﬀects of β-glucan are mainly attributed to
its physicochemical and structural characteristics interacting
with the gastrointestinal tract, as reﬂected by its ability to
generateviscous solutions at low concentrations in the upper
partofthegastrointestinaltractandtoundergofermentation
in the colon.
Although the physiological eﬀects of ingested β-glucan
are similar to other soluble ﬁbers, its availability and ease of
handling leads it to be increasingly incorporated into foods
with the purpose of increasing daily ﬁber consumption.
However, challenges in incorporating β-glucan into some
food items without compromising their sensorial properties
and their acceptance by consumers do still exist, and need to
be resolved.
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